Abstract
Despite advances in cardiovascular care in recent decades, mortality in cardiogenic shock remains high at approximately 50%. Mechanical circulatory support (MCS) in cardiogenic shock (CS) with percutaneous left ventricular assist devices (PVAD) has emerged as a potential solution to this. Though encouraging observational studies have been presented from areas around the world, there is a paucity of Canadian data. We describe a five-year experience with PVAD for CS at a single Canadian tertiary care centre.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
